The Parker Institute for Cancer Immunotherapy has partnered with dozens of organizations to develop a cancer vaccine to prevent the disease which is expected to grow by an additional 21.7 million through 2030. The plan is to target genetic markers specific to tumors to allow the body to generate an immune response to combat the cancer before it ever takes hold.